Site KR82004

Seoul 138-736

1 studies enrolling now · 11 studies all time

What they study most

Acute Myeloid Leukemia, Advanced Hepatocellular Carcinoma, Advanced Solid Tumors, Bladder Cancer, Carcinoma, Transitional Cell, Leukemia, Acute Myeloid (AML), Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone Sensitive Prostate Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Pancreatic Cancer

Studies at this site

• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study — Recruiting now
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer — Recruiting now
• A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer — Running, not enrolling
• A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) — Completed
• A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation — Completed
• A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) — Completed
• A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide — Completed
• A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma — Completed
• A Study of ASP1951 in Subjects With Advanced Solid Tumors — Stopped early
• A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors — Completed
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer — Completed